Correspondence concerning claims against Great Britain, transmitted to the Senate of the United States in answer to the resolutions of December 4 and 10, 1867, and of May 27, 1868.

Vols. 1-5 published also as Senate ex. doc. no. 11, 41st Cong., 1st sess., having serial no. 1394-1398.

Argument at Geneva : a complete collection of the forensic discussions on the part of the United States and of Great Britain before the Tribunal of arbitration under the Treaty of Washington /

Mode of access: Internet.

The case of Great Britain as laid before the Tribunal of arbitration, convened at Geneva under the provisions of the treaty between the United States of America and Her Majesty the queen of Great Britain, concluded at Washington, May 8, 1871..

Mode of access: Internet.

Papers relating to the Treaty of Washington.

v. 1-4. Geneva arbitration -- v. 5. Berlin arbitration -- v. 6. Washington arbitration and general appendix containing the report of Robert S. Hale.

The case of the United States, to be laid before the Tribunal of arbitration, to be convened at Geneva : under the provisions of the treaty between the United States of America and Her Majesty the Queen of Great Britain, concluded at Washington, May 8, 1871.

Prepared by J.C. Bancroft Davis.

William Ewart Gladstone. A biographical study.

The plates and portraits are printed on both sides.

Treatment discontinuation among breast, colorectal, and prostate cancer patients in Alabama

Introduction. Cancer registries provide information about treatment initiation but not the full course of treatment. In an effort to identify patient reported reasons for discontinuing cancer treatment, patients with prostate, breast, and colorectal cancer were identified from Alabama State Cancer Registry (ASCR) -Alabama Medicare linked database for interview. This study has two specific aims: (1) determine whether the ASCR-Medicare database accurately reflects patients’ treatment experiences in terms of whether they started and completed treatment when compared to patient self-report and (2) determine which patient demographic and health care system factors are related to treatment completion as defined by patient self-report. ^ Methods. The ASCR-Medicare claims dataset supplemented patient interview responses to identify treatment initiation and completion among prostate, breast, and colorectal cancer patients in Alabama from 1999-2003. Kappa statistic was used to test for concordance of treatment initiation and completion between patient self-report and Medicare claims data. Patients who reported not completing treatment were asked questions to ascertain reasons for treatment discontinuation. Logistic regression models were constructed to explore the association of patient and tumor characteristics with discontinuation of radiation and chemotherapy. ^ Results. Overall, there was a fair agreement across all cancer sites about whether one had surgery (Kappa=.382). There was fair agreement between self-report and Medicare claims data for starting radiation treatment (Kappa=.278). For starting chemotherapy there was moderate agreement (Kappa=.414). There was no agreement for completing treatment for radiation and chemotherapy between the self-report and claims data. Patients most often reported doctor’s recommendation (40% for radiation treatment and 21.4% for chemotherapy) and side effects (30% for radiation treatment and 42.8% for chemotherapy) for discontinuing treatment. Females were less likely to complete radiation than males (OR=.24, 95% CI=.11–.50). Stage I patients were more likely to drop radiation treatment than stage III patients (OR=3.34, 95% CI=1.12–9.95). Younger patients were more likely to discontinue chemotherapy than older patients (OR=2.84 95%, CI=1.08–7.69) and breast cancer patients were less likely to discontinue chemotherapy than colorectal patients (OR=.13, 95% CI=.04–.46). ^ Conclusion. This study reveals that patients recall starting treatment more accurately than completing treatment and that there are several demographic and tumor characteristics that influence treatment discontinuation. Providing patients with treatment summaries and survivorship plans can help patients their follow-up care when there are gaps in treatment recall and discontinuation of treatment.^

Performativity and the claims of scientificity of modern linguistics

This paper discusses the claim of the situatedness of research in both theoretical and applied linguistics and some of its implications and argues that it is linked to the performativity of all assertions, including scientific ones. More importantly, I argue that it is the regressive infinity of performativity that makes inevitable the passage from presumably 'dispassionate' research to militancy.

Matching prescription claims with medication data for nursing home residents: Implications for prescriber feedback, drug utilisation studies and selection of prescription claims database

Medication data retrieved from Australian Repatriation Pharmaceutical Benefits Scheme (RPBS) claims for 44 veterans residing in nursing homes and Pharmaceutical Benefits Scheme (PBS) claims for 898 nursing home residents were compared with medication data from nursing home records to determine the optimal time interval for retrieving claims data and its validity. Optimal matching was achieved using 12 weeks of RPBS claims data, with 60% of medications in the RPBS claims located in nursing home administration records, and 78% of medications administered to nursing home residents identified in RPBS claims. In comparison, 48% of medications administered to nursing home residents could be found in 12 weeks of PBS data, and 56% of medications present in PBS claims could be matched with nursing home administration records. RPBS claims data was superior to PBS, due to the larger number of scheduled items available to veterans and the veteran's file number, which acts as a unique identifier. These findings should be taken into account when using prescription claims data for medication histories, prescriber feedback, drug utilisation, intervention or epidemiological studies. (C) 2001 Elsevier Science Inc. All rights reserved.

Resistência de variedades de algodão ao curuquerê do algodoeiro Alabama argillacea Hubner (lepidoptera: noctuidae)

Este trabalho teve como objetivo verificar a ocorrência das formas de resistência, tais como: a não preferência para oviposição, a não preferência para alimentação e a antibiose, em variedades de algodoeiro (Gossypium hirsutum L.), à Alabama argillacea (Hubner, 1818), em experimentos de laboratório (27 ± 2 ºC, 70 ± 10% de U.R. e fotofase de 14 horas). Para avaliar a não preferência para oviposição e para a alimentação em teste com chance de escolha, adotou-se o delineamento em blocos casualizados e, no teste sem chance, o inteiramente casualizado. Para avaliar a antibiose, foram fornecidas às larvas, diariamente, folhas das variedades DeltaOpal, NuOpal, FMT 701, FMX 910 e 20 FMX 996. Durante este processo, verificou-se a duração de cada fase do inseto, avaliando-se a massa de larvas aos dez dias de idade, massa de pupas com 24 horas, período larval, pré-pupal e pupal, longevidade de adultos, viabilidade total e fecundidade. As variedades NuOpal e FMT 701 apresentam resistência do tipo não preferência para alimentação. As variedades NuOpal, FMT 701 e FMX 910 apresentam resistência do tipo antibiose em relação a A. argillacea.

How CSR claims in advertising affect children’s preferences and purchase intentions

A Work Project, presented as part of the requirements for the Award of a Masters Degree in Management from the NOVA – School of Business and Economics